Katherine Walsh, MD, Hematology, Columbus, OH, Ohio State University Wexner Medical Center

KatherineJWalshMD

Hematology Columbus, OH

Associate Professor of Clinical Internal Medicine and Clerkship Director for the third year medical student Inpatient IM Clerkship, Ohio State University College of Medicine

Dr. Walsh is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Walsh's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFELLOWSHIP
  • University of Florida
    University of FloridaRESIDENCY
  • University of Florida College of Medicine
    University of Florida College of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2011 - 2021
  • NC State Medical License
    NC State Medical License 2008 - 2012
  • GA State Medical License
    GA State Medical License 2007 - 2011
  • American Board of Internal Medicine Medical Oncology
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
    Katherine J. Walsh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
    Katherine J. Walsh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
    Katherine J. Walsh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

Hospital Affiliations